Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: A Wisconsin Oncology Network Phase II study

Investigational New Drugs

Volumn 32, Issue 1, 2014, Pages 195-199

  Hoang, Tien ^a   Campbell, Toby C ^a   Zhang, Chong ^a   Kim, KyungMann ^a   Kolesar, Jill M ^a   Oettel, Kurt R ^b   Blank, Jules H ^c   Robinson, Emily G ^d   Ahuja, Harish G ^e   Kirschling, Ron J ^f   Johnson, Peter H ^g   Huie, Michael S ^a   Wims, Mary E ^a   Larson, Martha M ^a   Hernan, Hilary R ^a   Traynor, Anne M ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^c Green Bay Oncology   (United States)

^d Mercy Regional Cancer Center   (United States)

^e Aspirus Cancer Center   (United States)

^f UW Cancer Center/Riverview   (United States)

^g ProHealth Care Regional Cancer Center   (United States)

Author keywords

Bortezomib; Non small cell lung cancer; Third line; Vorinostat

Indexed keywords

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PYRAZINES; TREATMENT OUTCOME;

EID: 84899061436     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9980-5     Document Type: Article

References (12)

1. Boyer M, Horwood K, Pavlakis N et al (2012) Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study. Asia Pac J Clin Oncol 8:248-254
2. Komatsu N, Kawamata N, Takeuchi S et al (2006) SAHA, a HDAC inhibitor, has profound anti-growth activity against nonsmall cell lung cancer cells. Oncol Rep 15:187-191
3. Traynor AM, Dubey S, Eickhoff JC et al (2009) Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol 4:522-526
4. Schenkein DP (2005) Preclinical data with bortezomib in lung cancer. Clin Lung Cancer 7(Suppl 2):S49-S55
5. Davies AM, Lara PN Jr, Mack PC, Gandara DR (2007) Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 13:s4647-s4651
6. Denlinger CE, Rundall BK, Jones DR (2004) Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 128:740-748 (Pubitemid 39388930)
7. Schelman W, Kolesar J, Schell K et al (2007) A phase I study of vorinostat in combination with bortezomib in refractory solid tumors. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25:Abstr. 3573
8. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246
9. Camidge DR, Bang YJ, Kwak EL et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13:1011-1019
10. Ramalingam SS, Maitland ML, Frankel P et al (2010) Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 28:56-62
11. Scagliotti GV, Germonpre P, Bosquee L et al (2010) A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 68:420-426
12. Jones DR, Moskaluk CA, Gillenwater HH et al (2012) Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer. J Thorac Oncol 7:1683-1690